Chair of the IAPRD 2018 Scientific Program Executive Committee, Hubert Fernandez (Cleveland Clinic, Cleveland, OH, US), discusses identification of patients with Parkinson’s disease (PD) at risk of cognitive decline, the advantages of levodopa-carbidopa intestinal gel in advanced PD, recent exciting advances in PD therapy, as well as strengths and highlights of this year’s meeting.
1. How can we best identify patients with Parkinson’s disease (PD) at risk of cognitive decline? (0:14)
2. What are the advantages of levodopa-carbidopa intestinal gel in advanced PD? (3:00)
1. What do you consider the most exciting advances in PD therapy in recent years? (0:14)
2. What do consider are the greatest strengths of the IAPRD meeting? (3:57)
3. What do you expect to be the highlights of IAPRD 2018? (5:08)
Filmed at the XXII World Congress on Parkinson’s Diseases and Related Disorders (IAPRD), Lyon, France, August 2018.
Speaker disclosure (over the past 12 months).
Grants/Research Support: Dr. Fernandez has received research support from Abbvie, Acadia, Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, but has no owner interest in any pharmaceutical company.
Honoraria: Dr. Fernandez has received honoraria from Prime Education Inc. International Parkinson and Movement Disorders Society, Carling Communications, Medscape, as a speaker in CME events. Dr. Fernandez has received honoraria from AbbVie, Biogen, GE Health Care, Inventiv, Kyowa Hakko Kirin, Lundbeck, Medscape, Merz Pharmaceuticals, Voyager, Sunovion, and Pfizer Pharmaceuticals, as a consultant.
Royalty: Dr. Fernandez has received royalty payments from Demos Publishing for serving as a book author/editor.
Contractual Services: The Cleveland Clinic has a contract with Teva for Dr. Fernandez’ role as a Co-Principal Investigator in SD-809 Tardive Dyskinesia global studies. Dr. Fernandez also serves as a member of the publication committee for Acorda Pharmaceuticals but does not receive any personal compensation for these.
Other: Dr. Fernandez has received a stipend from International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS Web Site.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!